Kazia Therapeutics actively collaborates with leaders across academia, the scientific community and research institutes to bring new patient therapies to life.

Over the years, Kazia Therapeutics has worked with leading academics in the field of actin cytoskeleton including Prof Peter Gunning laboratory (originally at Children’s Hospital at Westmead and then at UNSW Australia) and leading philanthropic organization, The Kids Cancer Project.

In developing Cantrixil to the stage of clinical trial, Kazia Therapeutics has worked with Yale University. The company is currently identifying suitable centres within the US and Australia for the First In Human, Phase 1 Study.

Trilexium is in early-stage development and Kazia Therapeutics is working with global R&D collaborators with whom Kazia Therapeutics aims to identify biomarkers of activity, delve deeper into the mechanism of action, and complete proof of concept studies.

Kazia Therapeutics currently collaborates with leading academic institutes worldwide, including The University of York, The Children’s Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston.

If you would like to collaborate with us, contact Dr Gordon Hirsch, Chief Medical Officer, gordon.hirsch@kaziatherapeutics.com.